...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer
【24h】

Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer

机译：术前Ca-125作为铂敏感浆液癌术后术后结果的预测因素

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: The purpose of the study was to evaluate whether preoperative cancer antigen 125 (CA-125) levels predict outcome of secondary cytoreductive surgery (SCS) in patients with serous recurrent ovarian cancer and whether this could be used as a prognostic factor for progression free (PFS) and overall (OS) survival. Patients and Methods: A cohort of 111 patients with first recurrence of platinum-sensitive serous ovarian cancer, who had undergone SCS at the Department of Gynecology and Oncological Surgery, Charite, Campus Virchow Clinic was analyzed in correlation with the preoperative CA-125 value. Results: The median preoperative CA-125 level was 164 U/ml. Complete tumor resection was achieved in 58.6% of the patients. PFS and OS for patients with preoperative CA-125 of less than 164.5 U/ml was significantly better than those with preoperative CA-125 = 164.5 U/ml (p=0.025 and p0.001, respectively). Conclusion: Preoperative CA-125 is not a statistically significant predictive factor for complete tumor resection after SCS. Preoperative CA-125 164.5 U/ml can predict significantly better PFS and OS for patients with first recurrence of platinum-sensitive ovarian cancer.
机译：目的：该研究的目的是评估术前癌症抗原125（CA-125）水平是否预测患有浆液复发性卵巢癌患者的继发性细胞凋亡（SCS）的结果，以及这是否可用作自由进展的预后因素（PFS）和总体（OS）生存。患者和方法：在与术前CA-125值相关的情况下，在妇产科和肿瘤外科，校园病毒诊所进行了111名患有铂敏感浆液癌癌症的111名患者的第一次复发患者。结果：中位数术前Ca-125水平为164 u / ml。在58.6％的患者中实现完全肿瘤切除术。对于术前Ca-125的患者的PFS和OS小于164.5 U / mL显着优于术前Ca-125＆gt的患者= 164.5u / ml（P = 0.025和P <0.001）。结论：术前Ca-125不是SCS后完全肿瘤切除的统计学显着的预测因素。术前Ca-125＆ 164.5 U / ml可以针对铂敏感卵巢癌的第一次复发的患者预测优异的PFS和OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号